Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Enhanced adoptive cell therapy

一种过继细胞、细胞的技术，应用在生命科学和医药领域，能够解决低效率、不安全、不可预测癌症疗法等问题，达到增加危险信号、毒性或损伤小、预防严重不良事件的效果

Active Publication Date: 2016-02-03
TILT BIOTHERAPEUTICS OY
View PDF4 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] It is an object of the present invention to provide simple methods and tools to overcome the above-mentioned problems of inefficient, unsafe and unpredictable cancer therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enhanced adoptive cell therapy
  • Enhanced adoptive cell therapy
  • Enhanced adoptive cell therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0144] Materials and Methods

[0145] B16-OVA animal model: Ovalbumin expressing B16 cells (B16-OVA) were maintained in RPMI, 10% FBS, 5 mg / ml G418, 20 mM L-glutamine, 1 x penicillin / streptomycin solution (GIBCO). 4-7 week old C57BL / 6 immunocompetent female mice were implanted subcutaneously in the right flank with 50 μl of RPMI, 2.5 x 10 in 0% FBS 5 B16-OVA cells, one tumor per mouse. Approximately 10 days after tumor implantation (when tumors became injectable, ∼3 mm minimum diameter), mice were grouped and in some experiments were injected intratumorally in 50 μl PBS or 1×10 in 50 μl PBS. 9 Viral particle (VP) oncolytic adenovirus treatment for six consecutive days. In other experiments, three injections were given on days 0, 2 and 4. Because mouse cells are intolerant of human adenovirus, multiple intratumoral virus injections were used to mimic viral replication-induced inflammation (Blair et al., 1989).

[0146] Adoptive transfer: On the first day of intratumoral t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.

Description

Field of Invention [0001] The present invention relates to the fields of life science and medicine. Specifically, the present invention relates to the treatment of cancer in humans. More specifically, the present invention relates to oncolytic adenoviral vectors used alone or in combination with therapeutic compositions for therapeutic uses and methods of treatment of cancer. In one aspect, the present invention relates to separate administration of an adoptive cell therapy composition and an oncolytic adenoviral vector. Furthermore, the present invention relates to pharmaceutical kits and pharmaceutical compositions both utilizing oncolytic adenoviral vectors. Background of the Invention [0002] For cancer treatment, new treatments are constantly being developed. Adoptive cell therapy (ACT) is an effective approach for the treatment of cancer, but can also be used to treat other diseases, such as infections and graft-versus-host disease. Adoptive cell transfer is the p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61K35/17A61K35/15C12N15/861A61P35/00
CPCA61K35/76C07K14/525C07K14/472C12N2710/10032C12N2710/10043A61P35/00A61P35/02A61P37/04A61P43/00A61K39/4611A61K2239/38A61K39/4644A61K2239/57A61K2300/00A61K35/761A61K38/19C12N15/86C12Q1/6806A61K38/00C12N7/00C12N15/861A61K35/17A61K48/00A61K2035/124C07K14/55C07K14/565C07K14/57C07K14/52C12N2710/10041
Inventor 阿克塞·赫敏基马库斯·瓦哈-科斯凯拉瑟瑞·塔提宁文森佐·赛鲁罗
Owner TILT BIOTHERAPEUTICS OY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com